FDA OKs immunotherapy drugs for bladder, blood cancers

U.S. regulators have approved the first drug for bladder cancer that harnesses the body's immune system.

The drug, developed by the Roche Group's Genentech unit, blocks a protein found on many tumor cells that deactivates key immune-system cells that kill cancer cells.